Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
15 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of veterinary internal medicine · 2017
Abstract Background Chronic diarrhea (CD) is common in dogs, and information on frequency and distribution of primary and secondary causes is lacking. Objectives To evaluate underlying causes and predictors of outcome in dogs with CD. Animals One hundred and thirty-six client-owned dogs with CD (≥3 weeks duration). Methods Retrospective review of medical records (Small Animal Clinic, Freie Universität Berlin, Germany, 09/2009-07/2011). Quantification of final diagnoses and comparison of clinical aspects including disease severity and clinicopathological abnormalities among dogs with clinical remission (either complete [gastrointestinal signs absent] or partial [clinical improvement of gastrointestinal signs and reduced episodes with shortened duration]), and those without recovery. Results Ninety percent of dogs were diagnosed with a primary enteropathy: inflammatory (71%; of those 66% dietary responsive, 23% idiopathic, 11% antibiotic responsive), infectious (13%), neoplastic (4%), and in one dog each mechanical disease or systemic vasculitis. Secondary causes were diagnosed in 10% of dogs: exocrine pancreatic (6%), endocrine (2%), and in one dog each hepatic, renal, and cardiac disease. In total, 87% of dogs had clinical remission, whereas 13% died or did not respond to treatment: Lack of recovery was frequently recorded for dogs with primary inflammatory (idiopathic) or neoplastic disease and was significantly associated with increased disease severity scores (P = .005), anemia (hematocrit < 40%, P < .001), severe hypoalbuminemia (serum albumin <2.0 g/dL, P = .008), and severe hypocobalaminemia (serum cobalamin concentration <200 pg/mL, P = .006). Conclusions and clinical importance Inflammatory enteropathies and particularly those of dietary origin were the most common causes of CD in dogs. Findings support the usefulness of hematocrit, and serum albumin and cobalamin concentration as prognostic markers in dogs with CD.
Arthritis and rheumatism · 2007
AbstractObjectiveRheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with unknown etiology and only partially defined pathogenesis. The aim of this study was to establish a murine model of chronic arthritis in which the development of tertiary lymphoid tissue, a hallmark of human RA, is locally induced, and to characterize the roles of the homeostatic chemokine receptors CXCR5 and CCR7 in this process.MethodsWe developed a modified model of chronic antigen‐induced arthritis (AIA) in mice with a strong bias toward inflammation. Disease pathology was assessed up to 9 months in wild‐type, CXCR5‐deficient, and CCR7‐deficient mice by determination of knee joint swelling and cellular and humoral immune responses, as well as by histologic analysis of arthritic knee joints.ResultsIn this novel model of AIA, mice developed organized ectopic lymphoid follicles with topologically segregated B cell and T cell areas, high endothelial venules, and germinal center formation within the chronically inflamed synovial tissue. Analysis of the initiation and progression of AIA in wild‐type, CXCR5−/−, and CCR7−/− mice revealed a reduction of acute inflammatory parameters in both knockout strains as well as significantly reduced joint destruction in CXCR5−/− mice. Most importantly, the development and organization of tertiary lymphoid tissue were significantly impaired in CXCR5‐deficient and CCR7‐deficient mice.ConclusionOur results suggest that an inflammatory microenvironment efficiently triggers lymphoid neogenesis in autoimmune diseases such as RA. Moreover, the generation of autoreactive tertiary lymphoid tissues, which is entirely dependent on homeostatic chemokines, may in turn maintain local aberrant chronic immune responses.
The Journal of antimicrobial chemotherapy · 2022
Abstract Objectives The unique properties of dalbavancin (DAL) emphasize the need to explore its clinical benefits to treat periprosthetic joint infections (PJIs). The present study aimed to compare the treatment outcome of dalbavancin with Standard of Care (SoC) in hip and knee PJIs. Methods Eighty-nine patients were selected for each group of this study based on our prospectively maintained PJI database. A 1:1 propensity score-matching was performed between patients who received at least two doses of dalbavancin and those who received SoC. Patients were matched based on demographics, joint, patient risk factors, Musculoskeletal Infection Society (MSIS) criteria, surgical management and type of infection. Treatment outcome was evaluated considering re-infection and re-revision rates, safety and tolerability of dalbavancin after a minimum of 1 year follow-up. Results Infection eradication was achieved in 69 (77.5%) and 66 (74.2%) patients of the DAL and SoC groups, respectively. Thirteen (14.6%) patients in the DAL group and 12 (13.5%) patients in the SoC group had an infection-related re-revision. The most prevalent microorganisms among the two groups were Staphylococcus epidermidis (32.3%), Staphylococcus aureus (13.8%) and Cutibacterium spp. (11.3%). There were significantly less Gram-positive bacteria (P = 0.03) detected in patients who received dalbavancin (17.4%) treatment compared with those treated with SoC (48.0%) in culture-positive re-revisions. Conclusions Dalbavancin treatment for Gram-positive PJIs resulted in a similar outcome to SoC, with excellent safety and low rate of adverse effects. Dalbavancin seems to be a promising antimicrobial against PJIs by reducing the risk of Gram-positive re-infections and allowing a less frequent dosage with potential outpatient IV treatment.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The Journal of antimicrobial chemotherapy · 2022 · Journal Article
Simon S, Frank BJH, Hartmann S, Hinterhuber L, et al.
Life (Basel, Switzerland) · 2021 · Journal Article
Yordanova IA, Ebner F, Schulz AR, Steinfelder S, et al.
Zeitschrift fur Rheumatologie · 2020 · Journal Article
Schwaneck EC, Streit A, Krone M, Hartmann S, et al.
Journal of veterinary internal medicine · 2017 · Journal Article
Volkmann M, Steiner JM, Fosgate GT, Zentek J, et al.
International immunopharmacology · 2015 · Journal Article
Zablotni A, Dakischew O, Trinkaus K, Hartmann S, et al.
International immunopharmacology · 2015 · Journal Article
Lips KS, Kneffel M, Willscheid F, Mathies FM, et al.
Journal of musculoskeletal & neuronal interactions · 2014 · Journal Article
Lips KS, Kauschke V, Hartmann S, Thormann U, et al.
PloS one · 2013 · Journal Article
Lips KS, Kauschke V, Hartmann S, Thormann U, et al.
Nature communications · 2013 · Journal Article
Baddack U, Hartmann S, Bang H, Grobe J, et al.
Life sciences · 2012 · Journal Article
Schubert J, Beckmann J, Hartmann S, Morhenn HG, et al.
Arthritis and rheumatism · 2007 · Journal Article
Wengner AM, Höpken UE, Petrow PK, Hartmann S, et al.
Journal of neurosurgery. Spine · 2020 · Case Reports
Kögl N, Dostal M, Örley A, Thomé C, et al.
The Annals of pharmacotherapy · 2004 · Clinical Trial
Hartmann SN, Rordorf CM, Milosavljev S, Branson JM, et al.
Journal of pharmacokinetics and pharmacodynamics · 2020 · Clinical Trial, Phase I
Hartmann S, Biliouris K, Naik H, Rabah D, et al.
Neurosurgical review · 2018 · Journal Article
Hartmann S, Kavakebi P, Wipplinger C, Tschugg A, et al.
Umsetzung der Verfahrensviefalt in den Masterstudiengängen „Klinische Psychologie und Psychotherapie“: Eine Onlineumfrage unter Studierenden und Absolvierenden
Die Umfrage wird an der Universität zu Köln (Prof. Dr. Ehrenthal, B.Sc Sophie Hartmann) durchgeführt. Sie untersucht die Umsetzung der Verfahrensvielfalt in den Masterstudiengängen Klinische Psychologie und Psychotherapi
Stadtentwicklung und Migration - Von Marginalisierung und Potentialen: Konsequenzen für eine kritische Berufspraxis der Soziokulturellen Animation im Spannungsfeld der Stadtentwicklung und Migration
Die Integrationskraft europäischer Städte schwindet, die soziale Ungleichheit wächst. Private Investoren dominieren vermehrt den Diskurs um die Verteilung des städtischen Raumes. Sozialräumliche Segregation und Gentrifiz
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).